Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Serum sickness and serum sickness-like reactions

INTRODUCTION

The cardinal features of serum sickness are rash, fever, and polyarthralgias or polyarthritis, which begin one to two weeks after first exposure to the responsible agent, and resolve within a few weeks of discontinuation. Although patients may appear very ill and uncomfortable during the acute febrile stage, the disease is self-limited and prognosis is excellent once the responsible drug is stopped.

This topic review will discuss serum sickness and serum sickness-like reactions, with an emphasis upon the biology and clinical features of serum sickness. A detailed discussion of hypersensitivity vasculitis, which has features similar to serum sickness, is presented separately. (See "Hypersensitivity vasculitis in adults" and "Hypersensitivity vasculitis in children".)

BACKGROUND

The term "serum sickness" was introduced by von Pirquet and Schick, who published a book with that title (Die Serumkrankheit) in 1905 [1]. The authors described an illness that developed in some patients after administration of horse serum that had been given as an antitoxin for the treatment of diphtheria and scarlet fever. They noted that there was a delay between administration of the horse serum and the development of the symptoms of serum sickness, and the delay was shorter if horse serum was administered again at a later time.

PATHOPHYSIOLOGY AND TERMINOLOGY

Lack of clarity about the meaning of the term "serum sickness" arose because it has been used to describe a variety of different, although related, syndromes. As mentioned previously, the classic clinical syndrome is caused by immunization of the host (human) by heterologous (nonhuman) serum proteins and subsequent illness caused by formation of immune complexes. However, the term also has been used to describe syndromes of rash, arthritis, and fever with onset several days to weeks following administration of a drug, or in association with some infectious diseases.

Serum sickness — Serum sickness is the prototypic example of the Gell and Coombs "type III" or immune complex mediated hypersensitivity disease (table 1) [2]. The reaction requires the presence of the antigen, coincident with antibodies directed against the antigen, leading to the formation of antigen-antibody or immune complexes. These should normally be cleared by the mononuclear phagocyte system, although if this system is not functioning well or is saturated by the immune complex load, then excess immune complexes may form in the circulation and deposit in tissues, or form directly in the involved tissues. Immune complexes may deposit preferentially in joints because the synovial endothelium is fenestrated (with more permeable pores or slits), and thus is more accessible to proteins and protein complexes, although the reason that immune complexes target specific tissues is not well understood. Once deposited, the presence of immune complexes in parenchymal tissues triggers an inflammatory response.

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Jan 31, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. von Pirquet CF, Schick B. (Die Serumkrankheit). Serum Sickness, Schick B (Ed), Williams & Wilkins, Leipzig 1905 (translation Baltimore 1951).
  2. Lawley TJ, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 1984; 311:1407.
  3. Vincent C, Revillard JP. Antibody response to horse gamma-globulin in recipients of renal allografts: relationship with transplant crises and transplant survival. Transplantation 1977; 24:141.
  4. Bielory L, Yancey KB, Young NS, et al. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol 1985; 13:411.
  5. Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore) 1988; 67:40.
  6. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994; 265:1095.
  7. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279:1052.
  8. Sylvestre D, Clynes R, Ma M, et al. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 1996; 184:2385.
  9. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16:421.
  10. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275.
  11. Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 2006; 26:705.
  12. Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med 1971; 134:7s.
  13. Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM. Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis 2009; 49:e18.
  14. Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. J Med Assoc Thai 2002; 85 Suppl 2:S607.
  15. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805.
  16. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356:1587.
  17. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.
  18. Zhang Z, Xiang Y, Wang B, et al. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr 2013; 172:537.
  19. Kunnamo I, Kallio P, Pelkonen P, Viander M. Serum-sickness-like disease is a common cause of acute arthritis in children. Acta Paediatr Scand 1986; 75:964.
  20. Vial T, Pont J, Pham E, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother 1992; 26:910.
  21. Lieberman P, Rice MC, Mallette JE Jr. Studies of urticaria and acute serum sickness with the C1q precipitin test. Arch Intern Med 1977; 137:440.
  22. Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis 2010; 55:141.
  23. Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med 2012; 19:121.
  24. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717.
  25. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542.
  26. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34:430.
  27. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol 2006; 135:147.
  28. Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005; 80:279.
  29. Rana JS, Sheikh J. Serum sickness-like reactions after placement of sirolimus-eluting stents. Ann Allergy Asthma Immunol 2007; 98:201.
  30. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325.
  31. Hamzaoglu H, Cooper J, Alsahli M, et al. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis 2010; 16:2109.
  32. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009; 23:101.
  33. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972.
  34. Abu-Elmagd KM, Costa G, Bond GJ, et al. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clin Transpl 2012; :155.
  35. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64:1331.
  36. Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010; 22:334.
  37. Saegeman V, Wynendaele W, Kerre S, et al. Transfusion-induced serum sickness. Transfusion 2009; 49:372.
  38. Reisman RE, Livingston A. Late-onset allergic reactions, including serum sickness, after insect stings. J Allergy Clin Immunol 1989; 84:331.
  39. Gaig P, García-Ortega P, Enrique E, et al. Serum sickness-like syndrome due to mosquito bite. J Investig Allergol Clin Immunol 1999; 9:190.
  40. Bonds RS, Kelly BC. Severe serum sickness after H1N1 influenza vaccination. Am J Med Sci 2013; 345:412.
  41. Warrington RJ, Martens CJ, Rubin M, et al. Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. J Allergy Clin Immunol 1987; 79:605.
  42. Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004; 292:1702.
  43. Milstien JB, Gross TP, Kuritsky JN. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. Pediatrics 1987; 80:270.
  44. Cruz NV, Bahna SL. Fever, urticaria, lymphadenopathy, and protracted arthralgia and myalgia resistant to corticosteroid therapy. Allergy Asthma Proc 2011; 32:395.
  45. Hunt KJ, Sobotka AK, Valentine MD, et al. Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978; 61:48.
  46. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567.
  47. Borden J, Fonkalsrud E, Newcomer V. Snake bite: treatment by isolation perfusion technique. Surgery 1961; 49:303.
  48. Morales C, Brasó JV, Pellicer A, et al. Serum sickness due to bovine serum albumin sensitization during in vitro fertilization. J Investig Allergol Clin Immunol 1994; 4:246.
  49. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13:94.
  50. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97:1408.
  51. LoVecchio F, Welch S, Klemens J, et al. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med 1999; 34:615.
  52. Kunkel DB, Curry SC, Vance MV, Ryan PJ. Reptile envenomations. J Toxicol Clin Toxicol 1983- 1984; 21:503.
  53. Shemesh IY, Kristal C, Langerman L, Bourvin A. Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome. Toxicon 1998; 36:867.
  54. Jurkovich GJ, Luterman A, McCullar K, et al. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28:1032.
  55. Vozianova ZhI, Chepilko KI. [Serum sickness in diphtheria]. Lik Sprava 1999; :126.
  56. Suwansrinon K, Jaijareonsup W, Wilde H, et al. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 2007; 101:206.
  57. Sène D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60:3848.
  58. Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995; 21:660.
  59. Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181.
  60. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030.
  61. Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671.
  62. Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol 2006; 6:3.
  63. Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann Allergy Asthma Immunol 2001; 86:330.
  64. Misirlioglu ED, Duman H, Ozmen S, Bostanci I. Serum sickness-like reaction in children due to cefditoren. Pediatr Dermatol 2012; 29:327.
  65. Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol 2006; 5:284.
  66. Heckbert SR, Stryker WS, Coltin KL, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132:336.
  67. Stricker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45:1177.
  68. King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health 2003; 39:677.
  69. Starnes L, Patel T, Skinner RB. Urticaria multiforme--a case report. Pediatr Dermatol 2011; 28:436.
  70. Shah KN, Honig PJ, Yan AC. "Urticaria multiforme": a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics 2007; 119:e1177.
  71. Emer JJ, Bernardo SG, Kovalerchik O, Ahmad M. Urticaria multiforme. J Clin Aesthet Dermatol 2013; 6:34.
  72. Joubert GI, Hadad K, Matsui D, et al. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol 1999; 6:197.
  73. Grammer LC. Cefaclor serum sickness. JAMA 1996; 275:1152.
  74. Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007; 13:647.
  75. Bayraktar F, Akinci B, Demirkan F, et al. Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis. Diabet Med 2009; 26:659.
  76. Erffmeyer JE. Serum sickness. Ann Allergy 1986; 56:105.